NCT04576858招募中不适用
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,950
- 试验地点
- 1
- 主要终点
- Time to recurrence
研究概览
简要总结
This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for
- Surgical resection + perioperative chemotherapy (cohort 1)
- Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2)
- Definitive chemoradiotherapy with curative intent (cohort 3)
- Systemic therapy with the intent to prolong survival (cohort 4)
- Palliative treatment without the use of chemotherapy (cohort 5)
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Gastroesophageal cancer Age 18 years or older Able to understand and sign written informed consent
排除标准
- •Patients not providing informed consent
结局指标
主要结局
Time to recurrence
时间窗: 1 year
次要结局
- Time to progression(1 year)
- Overall survival(5 year)
- Response rate RECIST 1.1(through study completion, an average of 1 year)
- Response duration RECIST 1.1(through study completion, an average of 1 year)
研究者
Morten Mau-Sørensen
Chief Physician, MD, PhD
Rigshospitalet, Denmark
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast CancerCirculating Tumor DNAGene AbnormalityMetastatic Breast CancerNCT05427617Hunan Cancer Hospital223
已完成
不适用
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast CancerCirculating Tumor DNAGene AbnormalityMetastatic Breast CancerNCT05079074Hunan Cancer Hospital223
Unknown
不适用
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic CancerPancreatic CancerNCT03214991Ji Kon Ryu100
招募中
不适用
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of ResectabilityPDAC - Pancreatic Ductal AdenocarcinomaNCT05853198Azienda Ospedaliera Universitaria Integrata Verona165
招募中
不适用
Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic InterventionMetastatic Colorectal CancerNo Evidence of Disease StatusctDNA MonitoringNCT05635630Fudan University110